Article
Radiology, Nuclear Medicine & Medical Imaging
Ryo Kurokawa, Akifumi Hagiwara, Mariko Kurokawa, Benjamin M. M. Ellingson, Akira Baba, Toshio Moritani
Summary: This study explored the ability of whole tumor ADC histogram profiles to differentiate between the presence and absence of grade 4 molecular features in histologically lower-grade gliomas. The results showed that the entropy of ADC histogram and age at diagnosis were independent predictive parameters, which could serve as potential imaging biomarkers for predicting grade 4 gliomas.
EUROPEAN RADIOLOGY
(2023)
Article
Oncology
Jasmin Jo, Martin J. van den Bent, Burt Nabors, Patrick Y. Wen, David Schiff
Summary: For IDH-mutant gliomas, there is still confusion on how to conduct long-term surveillance and imaging follow-up. Existing guidelines do not clearly specify individualized imaging guidelines based on treatment and tumor recurrence. In this study, we review current knowledge and propose recommended MRI surveillance intervals, as well as summarize situations where additional imaging studies may be advisable outside of the specified intervals.
Article
Clinical Neurology
Erik A. Williams, Priscilla K. Brastianos, Hiroaki Wakimoto, Amir Zolal, Mariella G. Filbin, Daniel P. Cahill, Sandro Santagata, Tareq A. Juratli
Summary: This study comprehensively characterized H3F3A-mutant diffuse gliomas in pediatric and adult patients, finding similar occurrence rates of H3K27M-mutant DMG in both groups and higher rates of targetable alterations in cell-cycle pathway genes in H3G34-mutant DHG.
ACTA NEUROPATHOLOGICA
(2023)
Article
Neurosciences
Banu Sacli-Bilmez, Ayca Ersen Danyeli, M. Cengiz Yakicier, Fuat Kaan Aras, M. Necmettin Pamir, Koray Ozduman, Alp Dincer, Esin Ozturk-Isik
Summary: This study analyzed the metabolic correlates of survival in Glioblastoma, IDH-wildtype, WHO grade-4 patients using H-1-MRS and found that Glx and GSH are important metabolic factors for patient survival.
FRONTIERS IN NEUROSCIENCE
(2023)
Article
Immunology
Zhicheng Hu, Shanqiang Qu
Summary: This study identifies the overexpression of EVA1C in glioma, which is closely associated with high infiltration levels of multiple immune cells and poor prognosis. EVA1C may serve as a potential biomarker for predicting high immune infiltration in WHO grade II/III gliomas.
FRONTIERS IN IMMUNOLOGY
(2021)
Article
Genetics & Heredity
Gang Wang, Wei Du, Lingyi Che, Xianzheng Gao, Ruihua Zhao, Juan Duan, Zhuoyu Gu, Qian Ma
Summary: PLAGL2 is implicated in the development and progression of various malignancies, including glioblastoma, with dysregulated expression commonly observed. Its overexpression in high-grade glioma (HGG) is associated with poor prognosis and potential therapeutic target, making it an independent prognostic biomarker in HGG patients.
FRONTIERS IN GENETICS
(2022)
Article
Medicine, Research & Experimental
Nan Zhang, Hao Zhang, Wantao Wu, Ran Zhou, Shuyu Li, Zeyu Wang, Ziyu Dai, Liyang Zhang, Fangkun Liu, Zaoqu Liu, Jian Zhang, Peng Luo, Zhixiong Liu, Quan Cheng
Summary: The study identifies tumor-infiltrating immune cell-associated lncRNAs (TIIClncRNAs) in low-grade glioma (LGG) and shows that these lncRNAs can predict immunotherapy outcomes.
Article
Clinical Neurology
Mia D. Sorensen, Ole Nielsen, Guido Reifenberger, Bjarne W. Kristensen
Summary: The study reveals that IDH mutation is associated with decreased levels of TIM-3(+) cells and reduced interactions between TIM-3(+) T cells and galectin-9(+) microglia/macrophages in astrocytic gliomas.
Article
Oncology
A. Reum Kim, Kyu Sung Choi, Min-Sung Kim, Kyung-Min Kim, Ho Kang, Sojin Kim, Tamrin Chowdhury, Hyeon Jong Yu, Chae Eun Lee, Joo Ho Lee, Soon-Tae Lee, Jae Kyung Won, Jin Wook Kim, Yong-Hwy Kim, Tae Min Kim, Sung-Hye Park, Seung Hong Choi, Eui-Cheol Shin, Chul-Kee Park
Summary: Quantifying tumor-infiltrating immune cells helps understand the heterogeneity of the immune microenvironment in HGG, which has prognostic implications. Radiomic signatures can predict this immune microenvironment non-invasively.
CANCER IMMUNOLOGY IMMUNOTHERAPY
(2021)
Review
Oncology
Maximilian J. Mair, Marjolein Geurts, Martin J. van den Bent, Anna S. Berghoff
Summary: WHO grade II-III gliomas are rare primary brain tumors with longer median survival compared to grade IV glioblastoma. Treatment involves maximal safe resection and adjuvant therapies, with challenges in conducting clinical trials due to rarity and long follow-up times. The 2016 WHO Classification introduced a molecular diagnostic framework for more homogenous subgroups. Available evidence for adjuvant treatment was generated pre-molecular era, emphasizing the need for further research in this field.
CANCER TREATMENT REVIEWS
(2021)
Article
Oncology
Louise Carstam, Alba Corell, Anja Smits, Anna Denes, Hanna Barcheus, Klara Modin, Helene Sjogren, Sandra Ferreyra Vega, Thomas Olsson Bontell, Helena Caren, Asgeir Store Jakola
Summary: This study found that WHO grade is not a reliable prognostic factor in molecularly well-defined diffuse lower-grade glioma (dLGG). However, preoperative tumor volume remains associated with prognosis in IDH-mutated astrocytomas and oligodendrogliomas.
FRONTIERS IN ONCOLOGY
(2022)
Article
Biochemistry & Molecular Biology
Daisuke Saito, Masahiko Imai, Chiho Yamada, Noriko Takahashi
Summary: Retinoic acid (RA) increases alpha-actinin-4 protein levels, alters its intracellular localization, and inhibits ubiquitination and proteasomal degradation, playing a role in cell differentiation.
BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR CELL RESEARCH
(2021)
Article
Medicine, General & Internal
Songbo Shen, Yiqun Yao
Summary: The expression of AKIP1 is positively associated with World Health Organization grade in glioma patients, and high expression is associated with worse overall survival, especially in high-grade glioma patients. AKIP1 expression is also negatively associated with overall survival in all subgroups of patients with or without adjuvant radiotherapy or chemotherapy. Further multivariate Cox's regression analysis showed that high AKIP1 expression is an independent predictive factor for worse overall survival, indicating its potential as a novel biomarker for tumor management and prognosis surveillance in glioma patients.
Article
Genetics & Heredity
Adria-Jaume Roura, Bartlomiej Gielniewski, Paulina Pilanc, Paulina Szadkowska, Marta Maleszewska, Sylwia K. Krol, Ryszard Czepko, Wojciech Kaspera, Bartosz Wojtas, Bozena Kaminska
Summary: Most somatic mutations found in primary HGGs were not present in recurrent tumors, suggesting subclone substitution during tumor progression. Transcriptomic changes and immune-related signatures distinguish recurrent HGGs, showing a prominent infiltration of immature dendritic cells and M2 macrophages.
JOURNAL OF MOLECULAR MEDICINE-JMM
(2021)
Review
Oncology
Pushan Dasgupta, Veerakumar Balasubramanyian, John F. F. de Groot, Nazanin K. K. Majd
Summary: Preclinical models are crucial for understanding glioma biology and developing therapeutics. However, the development of ideal models is challenging due to various factors, such as genetic background, tumor heterogeneity, intact blood-brain barrier, and the tumor microenvironment. In this review, we discuss in vitro and in vivo models of glioma and the challenges involved in developing optimal models.